StockData
Kymera Therapeutics, Inc. logo

Kymera Therapeutics, Inc. (KYMR) income statement

KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30227% above fair value
$121.13−0.39 (-0.32%)

Close on Nov 18, 2026Market cap $10.34BP/E –Yield –

Kymera Therapeutics, Inc. income statement

Ratios

Latest available, balances at Sep 30, 2026

Profitability, TTM

Gross margin
0.0%
Operating margin
-396.0%
Net margin
-341.8%
Return on equity, FY2025
-25.8%

Financial strength

Current ratio
11.13
Debt to equity
–
Debt to assets
–
Cash to current liabilities
416.1%

Valuation

P/E ratio
–
Price to sales
101.15
Price to book
6.40
Dividend yield
–

See a number that looks wrong?